REG - Nuformix PLC - Result of AGM

NuformixAnnouncement

19/03/2024 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240319:nRSS4695Ha&default-theme=true

RNS Number : 4695H  Nuformix PLC  19 March 2024

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that
the Annual General Meeting ("AGM") of Nuformix plc was held earlier today and
all resolutions put to shareholders were duly passed and approved by way of a
poll vote.  The results of the poll, including proxies received ahead of the
AGM, are reported below:

     Resolution                                                                      Ordinary/ Special  For                   Against              Total votes cast
                                                                                                        No. of votes  %       No. of votes  %
 1   To receive the annual report and accounts for the year ended 30 September 2023  Ordinary           142,381,407   97.38%  3,824,784     2.62%  146,206,191

 2   To approve the annual report on remuneration                                    Ordinary           142,812,526   97.60%  3,505,839     2.40%  146,318,365

 3   To re-appoint Daniel Gooding as a director                                      Ordinary           141,901,631   97.81%  3,179,490     2.19%  145,081,121

 4   To re-appoint Julian Gilbert as a director                                      Ordinary           141,901,631   97.81%  3,179,490     2.19%  145,081,121

 5   To re-appoint Madeleine Kennedy as a director                                   Ordinary           141,881,631   97.75%  3,270,050     2.25%  145,151,681

 6   To re-appoint Kreston Reeves LLP as auditor                                     Ordinary           142,139,182   97.90%  3,055,316     2.10%  145,194,498

 7   To authorise the directors to determinethe auditor's fees                       Ordinary           141,874,740   97.71%  3,319,758     2.29%  145,194,498

 8   To authorise the directors to allot shares                                      Ordinary           136,385,306   93.95%  8,785,230     6.05%  145,170,536

 9   To authorise the directors to disapply pre-emption rights                       Special            134,565,189   92.73%  10,553,347    7.27%  145,118,536

 10  To authorise the Company to purchase its own shares                             Special            135,812,749   94.11%  8,504,877     5.89%  144,317,626

 11  To authorise calling of a general meeting on 14 clear days' notice              Special            142,106,241   97.84%  3,141,610     2.16%  145,247,851

A vote withheld is not a vote in law and is not counted in the calculation of
votes validly cast for or against a resolution.

The Company's issued share capital is 819,309,368 ordinary shares of £0.001
each.

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director                Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 Bob Pountney (Corporate Broking)                  +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical and Phase
1-ready assets with potential for significant value and early licensing
opportunities.

 

For more information, please visit www.nuformix.com
(http://www.nuformix.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGZKLFFZXLXBBV